|
Sub-category:
Epidemiology/Molecular Epidemiology
Category:
Tumor Biology/Immunobiology/Human Genetics
Meeting:
2003 ASCO Annual Meeting
Session Type and Session Title:
General Poster Session, Tumor Biology/Human Genetics
Abstract No:
3495
Citation:
Proc Am Soc Clin Oncol 22: 2003 (abstr 3495)
Author(s):
C. Verschraegen; University of New Mexico, Albuquerque, NM
Abstract:
BACKGROUND: This study was undertaken to evaluate incidence and survival rates for mesothelioma in the United States (US) using population-based data. METHODS: Overall and 5-year average age-adjusted incidence and survival rates were computed using the Surveillance, Epidemiology, and End-Results Public-Use database. RESULTS: Between 1973 and 1999, 5266 cases were recorded. The incidence rate for mesothelioma was 0.97 per 100,000. This incidence rate was age-adjusted to the 2000 U.S. standard. The incidence rates by sex showed a much higher incidence for men than for women, with 1.8 versus 0.4 per 100,000. By registry, rates were highest in the San Francisco and Seattle areas, and lowest in Atlanta. By races, the incidence rates were highest for whites, followed by blacks, then others. The median age at diagnosis was between 65 and 69 years old for males and females. The 5-year average age-adjusted relative survival rate over these 27 years was 8% overall, 5% for men, 17% for women. The percentages of mesothelioma per anatomical sites were for men, pleura, 90.2%; abdominal cavity, 8.3%; genital area, 0.7% and 0.4% for heart and other, and for women, pleura, 71.1%; abdominal cavity, 24.3%; heart, 1.6%; and 1.5% for genital system and other. CONCLUSIONS: In the United States, highest incidence is seen in geographic areas where shipyards are common, an epidemiologic evidence to link mesothelioma to asbestos exposure. Pleura is the most common anatomical site of origin for both sexes. Men are more at risk than women, but proportionally, women are more susceptible to develop peritoneal and pericardial disease. Although women survive longer than men, survival rates are poor, and more applied research needs to be funded to improve the prognosis of this disease.
 Associated Presentation(s):
Other Abstracts in this Sub-Category:
Abstracts by C. Verschraegen; University of New Mexico:
Presentations by C. Verschraegen; University of New Mexico:
Educational Book Manuscripts by C. Verschraegen; University of New Mexico:
|
